logo
logo
BioLineRx Ltd.

BioLineRx Ltd.

NASDAQ•BLRX
CEO: Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA
セクター: Healthcare
業種: Biotechnology
上場日: 2011-07-27
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
連絡先情報
Modi’in Technology Park, 2 HaMa’ayan Street, Hevel Modi'in, 7177871, Israel
972-8-642-9100
www.biolinerx.com
時価総額
$12.23M
PER (TTM)
-1.5
19.5
配当利回り
--
52週高値
$7.77
52週安値
$2.30
52週レンジ
9%
順位65Top 96.0%
1.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$4.94M+0.00%
直近4四半期の推移

EPS

-$1.47+1900.00%
直近4四半期の推移

フリーCF

$0.00+0.00%
直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

Massive Revenue Jump Total revenues reached $28.9M in 2024, a 502.1% increase, driven by upfront and milestone payments from licensing deals.
Net Loss Significantly Narrows Net loss improved substantially to ($9.2M) in 2024 from ($60.6M) in 2023, reflecting reduced operating expenses post-restructuring.
Successful Capital Raising Net cash provided by financing activities was $20.7M in 2024, supported by registered direct offerings completed in late 2024 and early 2025.
R&D Costs Decreased Research and development expenses fell 26.4% to $9.2M in 2024, following termination of AGI-134 development and US commercial shutdown.

リスク要因

Going Concern Material Uncertainty Management concluded substantial doubt about ability to continue as going concern, despite recent financing efforts providing runway through H2 2026.
Partner Commercialization Dependency Future revenue hinges on licensees (Ayrmid, Gloria) successfully commercializing APHEXDA across licensed territories and indications.
Israeli Geopolitical Instability Operations based in Israel face adverse effects from ongoing political, economic, and military instability in the region, impacting business continuity.
Biokine Arbitration Claim Biokine filed complaint seeking $6.5M damages for alleged breach; dispute referred to arbitration, outcome remains uncertain for proprietary technology rights.

見通し

Cash Runway Secured Existing cash and expected partnership inflows provide sufficient capital requirements through the second half of 2026.
Refocused Israeli Development Operations refocused on development activities in Israel for oncology and rare diseases, achieving a significantly reduced annual cash burn rate.
Pipeline Expansion Strategy Actively pursuing in-licensing opportunities to expand and diversify product pipeline, focusing on assets complementing core expertise in oncology/rare disease.
Future Financing Exploration Expect to continue exploring alternative financing sources, including future securities offerings and government grants, to support ongoing development objectives.

同業比較

売上高 (TTM)

Editas Medicine, Inc.EDIT
$46.38M
-24.9%
BioLineRx Ltd.BLRX
$17.25M
-21.6%
Mereo BioPharma Group plcMREO
$500.00K
-50.0%

粗利益率 (最新四半期)

Lyell Immunopharma, Inc.LYEL
100.0%
+0.0pp
Editas Medicine, Inc.EDIT
100.0%
+2621.3pp
BioLineRx Ltd.BLRX
83.4%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ANNX$602.76M-3.6-92.3%11.8%
REPL$599.48M-2.1-102.7%23.6%
LYEL$539.17M-1.4-96.7%10.9%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-25.1%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月30日
|
EPS:-$0.50
|
売上高:-
財務レポート
財務データ
ニュース
全年度

  • Form 20-F - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月31日|
    売上高: $28.94M+502.9%
    |
    EPS: $-0.12+87.8%
    予想を上回る

  • Form 20-F - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月26日|
    売上高: $4.80M+0.0%
    |
    EPS: $-0.94-95.3%
    予想を上回る

  • Form 20-F/A - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月26日|
    売上高: $4.80M+0.0%
    |
    EPS: $-0.94-95.3%
    予想を上回る

  • Form 20-F - FY 2022

    会計期末: 2022年12月31日|提出日: 2023年3月22日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.48+21.1%
    不明

  • Form 20-F/A - FY 2021

    会計期末: 2021年12月31日|提出日: 2022年9月9日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.61+66.0%
    不明

  • Form 20-F - FY 2021

    会計期末: 2021年12月31日|提出日: 2022年3月16日|修正版データを参照

  • Form 20-F - FY 2020

    会計期末: 2020年12月31日|提出日: 2021年2月23日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.80+33.3%
    不明